<DOC>
	<DOCNO>NCT01358734</DOCNO>
	<brief_summary>The study aim compare safety efficacy high-dose lenalidomide regimen , sequential azacitidine lenalidomide azacitidine person ≥65 year newly-diagnosed acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>A Study Being Conducted Multiple Locations Compare Safety Efficacy Three Different Regimens ; ( 1 ) High-Dose Lenalidomide ; ( 2 ) Lenalidomide + Azacitidine ; ( 3 ) Azacitidine Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>On September 11 , 2013 , randomization continuous 50 mg lenalidomide arm temporarily suspend base review data first 13 participant high rate discontinuation ( 11/13 participant ) . The Data Monitoring Committee assess study data September 20 , 2013 report safety concern . The high rate early discontinuation inconsistent treatment duration require test study primary endpoint survival one year . Consequently , Celgene decide reopen lenalidomide arm .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Newly diagnose acute myeloid leukemia ( AML ) , AML antecedent hematologic disorder therapyrelated AML Male female subject age ≥ 65 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 White blood cell ( WBC ) count ≤ 10 x 10⁹/L screen Previous treatment azacitidine , decitabine , cytarabine lenalidomide Previous cytotoxic biologic treatment kind AML prior use targeted therapy agent . Suspected proven acute promyelocytic leukemia Prior bone marrow stem cell transplantation Candidate allogeneic bone marrow stem cell transplantation AML antecedent hematologic disorder chronic myelogenous leukemia myeloproliferative neoplasm Presence malignant disease within previous 12 month exception</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>elderly</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>vidaza</keyword>
	<keyword>azacitidine</keyword>
	<keyword>elderly AML</keyword>
	<keyword>revlimid</keyword>
	<keyword>lenalidomide</keyword>
</DOC>